Home Health Care News February 21, 2025
Amid the U.S. Department of Justice’s (DOJ) legal battle with UnitedHealth Group (NYSE: UHG) regarding the planned purchase of Amedisys (Nasdaq: AMED), the company is also now reportedly facing an investigation for a different matter.
The DOJ is currently pursuing a civil fraud investigation focused on the company’s practices for recording diagnoses that activate extra payments to its Medicare Advantage (MA) plans, The Wall Street Journal reported Friday.
“The government regularly reviews all MA plans to ensure compliance and we consistently perform at the industry’s highest levels on those reviews,” UnitedHealth Group wrote in a press statement. “We are not aware of the ‘launch’ of any ‘new’ activity as reported by the Journal. We are aware, however, that the Journal...
Today's Sponsors
Today's Sponsor